Discriminating poststroke depression from stroke by nuclear magnetic resonance spectroscopy-based metabonomic analysis

Neuropsychiatric Disease and Treatment

Volumn 12, Issue , 2016, Pages 1919-1925

  Xiao, Jianqi ^a   Zhang, Jie ^b   Sun, Dan ^c   Wang, Lin ^a   Yu, Lijun ^a   Wu, Hongjing ^a   Wang, Dan ^a   Qiu, Xuerong ^a  

^a First Hospital of Qiqihar City   (China)

^b Central Hospital of Jiamusi City   (China)

^c Petrochina Daqing Oilfield   (China)

Author keywords

Metabonomic; NMR; Nuclear magnetic resonance; Poststroke depression; PSD; Stroke

Indexed keywords

ACETAMIDE; ALPHA GLUCOSE; ALPHA HYDROXYBUTYRIC ACID; ARABINITOL; BIOLOGICAL MARKER; FORMIC ACID; GLUTAMIC ACID; HYDROXYBUTYRIC ACID; LACTIC ACID; PHENYLALANINE; SARCOSINE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID ANALYSIS; AREA UNDER THE CURVE; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATTERN RECOGNITION; POSTSTROKE DEPRESSION; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; URINALYSIS;

EID: 84983488961     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S110613     Document Type: Article

References (22)

1. Allan LM, Rowan EN, Thomas AJ, Polvikoski TM, O’Brien JT, Kalaria RN. Long-term incidence of depression and predictors of depressive symptoms in older stroke survivors. Br J Psychiatry. 2013;203(6):453–460.
2. Meader N, Moe-Byrne T, Llewellyn A, Mitchell AJ. Screening for poststroke major depression: a meta-analysis of diagnostic validity studies. J Neurol Neurosurg Psychiatry. 2014;85(2):198–206.
3. Tu WJ, Dong X, Zhao SJ, Yang DG, Chen H. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischaemic stroke. J Neuroendocrinol. 2013;25(9):771–778.
4. Schmid AA, Kroenke K, Hendrie HC, Bakas T, Sutherland JM, Williams LS. Poststroke depression and treatment effects on functional outcomes. Neurology. 2011;76(11):1000–1005.
5. Saxena SK, Ng TP, Koh G, Yong D, Fong NP. Is improvement in impaired cognition and depressive symptoms in post-stroke patients associated with recovery in activities of daily living? Acta Neurol Scand. 2007;115(5):339–346.
6. Berg A, Lönnqvist J, Palomäki H, Kaste M. Assessment of depression after stroke: a comparison of different screening instruments. Stroke. 2009;40(2):523–529.
7. Chen JJ, Liu Z, Fan SH, et al. Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. Sci Rep. 2014;4:5855.
8. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008;48:653–683.
9. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature. 2008;455(7216):1054–1056.
10. Chen JJ, Huang H, Zhao LB, et al. Sex-specific urinary biomarkers for diagnosing bipolar disorder. PLoS One. 2014;9(12):e115221.
11. Yang J, Chen T, Sun L, et al. Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013;18(1):67–78.
12. Chen JJ, Zhou CJ, Liu Z, et al. Divergent urinary metabolic phenotypes between major depressive disorder and bipolar disorder identified by a combined GC-MS and NMR spectroscopic metabonomic approach. J Proteome Res. 2015;14(8):3382–3389.
13. Jung JY, Lee HS, Kang DG, et al. 1H-NMR-based metabolomics study of cerebral infarction. Stroke. 2011;42(5):1282–1288.
14. Goldstein M, Barnett HJM, Orgogozo JM, Sartorius N, Symon L, Vereschchagin NV. Report of the WHO Task Force on stroke and other crebrovascular disorders. Stroke. 1989;20(10):1407–1431.
15. Fang J, Yan W, Jiang GX, Li W, Cheng Q. Serotonin transporter gene polymorphism in Chinese patients with poststroke depression a case-control study. Stroke. 2011;42(5):1461–1463.
16. Zheng P, Wang Y, Chen L, et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol Cell Proteomics. 2013;12(1):207–214.
17. Zhan Y, Yang YT, You HM, et al. Plasma-based proteomics reveals lipid metabolic and immunoregulatory dysregulation in post-stroke depression. Eur Psychiatry. 2014;29(5):307–315.
18. Srivastava A, Taly AB, Gupta A, Murali T. Post-stroke depression: prevalence and relationship with disability in chronic stroke survivors. Ann Indian Acad Neurol. 2010;13(2):123–127.
19. Wei Z, Xin-an Z. A novel urinary metabolite signature for non-invasive post-stroke depression diagnosis. Cell Biochem Biophys. 2015;72(3):661–667.
20. MacIntyre DA, Jiménez B, Lewintre EJ, et al. Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia. 2010;24(4):788–797.
21. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS. MetaboAnalyst 2.0 – a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 2012;40(Web Server issue):W127–W133.
22. Williams R, Lenz EM, Wilson AJ, et al. A multi-analytical platform approach to the metabonomic analysis of plasma from normal and Zucker (fa/fa) obese rats. Mol Biosyst. 2006;2(3–4):174–183.